GeneDx Holdings (WGS) stock surged 6.41% in pre-market trading on Tuesday following the release of its third-quarter 2025 financial results. The company reported revenue that significantly exceeded analyst expectations, driving investor optimism.

According to the company's financial report, GeneDx posted Q3 revenue of $116.7 million, substantially surpassing the IBES estimate of $104.1 million. This impressive top-line performance likely sparked the pre-market rally as investors reacted positively to the company's ability to outperform market expectations.

While GeneDx reported a net loss of $7.6 million for the quarter, the company's adjusted net income stood at a positive $14.7 million. This adjusted figure, which typically excludes non-recurring items and provides a clearer picture of ongoing operations, may have further bolstered investor confidence in the company's financial health and growth trajectory. The strong revenue growth coupled with positive adjusted earnings suggests that GeneDx's business strategy and market positioning are yielding favorable results, potentially setting the stage for continued growth in the genomic diagnostics sector.